newsfilter
← Latest News
ACCESS Newswire·

Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

Ongoing preclinical studies with multiple data readouts expected throughout remainder of 2024Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma